Психосоциальная реабилитация

Количество литературы, посвященной психосоциальным методам помощи онкологическим

больным, возросло. Авторы указывают на необходимость приспособления психотерапии к

специфическому контексту онкологии (Bloch и Kissane, 2000), а также создания новых подходов

для работы со специфическими проблемами, возникающими в связи с раком. Уже сделаны

важные шаги в разработке психосоциальных вмешательств, ориентированных на запущенные

стадии болезни. В рамках этих состояний существует необходимо помогать пациентам

сохранить чувство собственного достоинства и развивать духовные аспекты, связанные с

приближением смерти (Breitbart, 2002; Chochinov et al., 2005).

 

В нескольких исследованиях показано, что психологические вмешательства могут

способствовать значительному улучшению качества жизни пациентов, а также уменьшению

выраженности эмоциональных симптомов, включая депрессию и дезадаптивные стили

преодоления стресса (отчаяние, тревожная озабоченность) (Sheard и Maguire, 1999). Точная

постановка диагноза и направление на подходящее психологическое вмешательство

необходимы для повышения вероятности «полезного эффекта» и снижения процента

отказавшихся от лечения. Психотерапия (в индивидуальном или групповом формате)

продемонстрировала наибольшую эффективность у больных раком с выраженными

симптомами депрессии, в то время как психотерапевтическая работа с пациентами, имеющими

«нормальный» уровень психологического дистресса, почти не эффективна (Coyne et al., 2006;

Fawzy et al., 1995).

 

Ранее предполагалось, что психотерапевтические вмешательства могут влиять на увеличение

продолжительности жизни больных раком (Spiegel et al., 1989). Однако в более поздних

исследованиях это предположение не подтвердилось, и никакого влияния психотерапии на

улучшение прогноза у больных раком обнаружено не было (Goodwin et al., 2001; Kissane et al.

2007; Spiegel et al., 2007).

 

В качестве общей рекомендации, вариантом выбора лечения депрессии у больных раком

является комбинация психологического воздействия и психофармакотерапии, подобранная в

соответствии с потребностями каждого конкретного пациента. Некоторые авторы связывают

положительную динамику в лечении психических заболеваний, особенно депрессий, с

наличием у клиницистов инструментов скрининга, правильной диагностики, а также

психологического и психофармакологического аспектов помощи (Akechi et al., 2007; Sharpe et

al., 2004). О схожих результатах сообщается и в связи с применением недавно разработанных

NCCN руководств, предназначенных для проведения поддерживающей терапии при

расстройствах настроения (Holland и Bultz, 2007; NCCN, 2008).

 

- 97 -

 

ВЫВОДЫ

Депрессия — важное коморбидное психическое расстройство, сопровождающее рак. Недавний

отчет Института медицины Национальной академии наук, «Всеобъемлющий уход за больным

раком: знакомство с психосоциальными аспектами здоровья», является важным ориентиром

для принятия мер в отношении депрессии и тревоги, которые часто развиваются у

онкологических больных (Комитет психосоциального обслуживания больных раком и их семей

в общественных учреждениях, 2007). В этом отчете приведена программа стандартных

мероприятий по психосоциальной поддержке больных раком. Важно, чтобы психиатры

работали вместе со своими коллегами и способствовали выработке наиболее эффективных

практических методик для скрининга и выявления депрессий и других психиатрических

проблем у пациентов, получающих лечение в онкологических учреждениях. Ко всему прочему,

необходимо проведение доказательных клинических исследований, направленных на

определение оптимальных методов лечения депрессии на всех стадиях заболевания и при всех

видах рака. По мере того, как разрабатываются новые технологии и более мощные

химиотерапевтические и не‐химиотерапевтические способы подвергаются клиническим

исследованиям, нам необходимо расширять свое понимание того, как это лечение влияет на

психиатрическое обслуживание пациентов и их семей.

 

- 98 -

 

СПИСОК ЛИТЕРАТУРЫ

Adams F, Quesada JR, Gutterman JU.

Neuropsychiatric manifestations of human

leukocyte interferon therapy in patients

with cancer. JAMA 1 984;252:938‐41.

 

Akechi T, Nakano T, Akizuki N, et al. Somatic

symptoms for diagnosing major

depression in cancer patients.

Psychosomatics 2003;44:244‐8.

 

Akechi T, Taniguchi K, Suzuki S, et al.

Multifaceted psychosocial intervention

program for breast cancer patients after

first recurrence: Feasibility study.

Psychooncology 2007;16:517‐24.

 

Akizuki N, Yamawaki S, Akechi T, et al.

Development of an Impact Thermometer

for use in combination with the Distress

Thermometer as a brief screening tool for

adjustment disorders and/or major

depression in cancer patients. J Pain

Symptom Manage 2005;29:91‐9.

 

Baile WF, Buckman R, Lenzi R, et al. SPIKES‐A

six‐step protocol for delivering bad news:

Application to the patient with cancer.

Oncologist 2000;5:302‐11.

 

Bloch S, Kissane D. Psychotherapies in psycho‐

oncology. An exciting new challenge. Br J

Psychiatry 2000;177:112‐6.

 

Boyd AD, Riba M. Depression and pancreatic

cancer. J Natl Compr Canc Netw

2007;5:113‐6.

 

Breitbart W, ed. The IPOS "pocket" handbook

of palliative care for the psycho‐

oncologist. IPOS Press, International

Psycho‐Oncology Society 2007 (www.ipos-

Breitbart W, Rosenfeld B, Pessin H, et al.

Depression, hopelessness, and desire for

hastened death in terminally ill patients

with cancer. JAMA 2000; 284:2907‐11.

 

Breitbart W. Spirituality and meaning in

supportive care: Spirituality‐ and meaning‐

centered group psychotherapy

interventions in advanced cancer. Support

Care Cancer 2002;10:272‐80.

 

Carney CP, Jones L, Woolson RF, et al.

Relationship between depression and

pancreatic cancer in the general

population. Psychosom Med

2003;65:884‐8.

 

Carroll JK, Kohli S, Mustian KM, et al.

Pharmacologic treatment of cancer‐

related fatigue. Oncologist 2007;12:43‐51.

 

Chaturvedi SK, Maguire P, Hopwood P.

Antidepressant medications in cancer

patients. Psychooncology 1995;3:57‐60.

 

Chochinov H, Wilson K, Enns M, et al. Are you

depressed? Screening for depression in

the terminally ill. Am J Psychiatry

1997;154:674‐6.

 

Chochinov HM, Hack T, Hassard T, et al.

Dignity therapy: A novel

psychotherapeutic intervention for

patients near the end of life. J Clin Oncol

2005;23:5520‐5.

 

Chochinov HM. Depression in cancer patients.

Lancet Oncol 2001;2:499‐505.

 

Clarke DM, Kissane DW, Trauer T, et al.

Demoralization, anhedonia and grief in

society.org).

 

- 99 -

 

patients with severe physical illness.

World Psychiatry 2005;4:96‐105.

 

Committee on Psychosocial Services to Cancer

Patients/ Families in a Community Setting,

Adler NE, Page AEK, eds. Cancer care for

the whole patient: Meeting psychosocial

health needs. Washington, DC: The

National Academies Press (Institute of

Medicine); October, 2007 (www.nap.

edu/catalog.php?record id=11993).

 

Couper JW, Bloch S, Love A, et al. The

psychosocial impact of prostate cancer on

patients and their partners. Med J Aust

2006;185:428‐32.

 

Coyne JC, Lepore SJ, Palmer SC. Efficacy of

psychosocial interventions in cancer care:

Evidence is weaker than it first looks. Ann

Behav Med 2006;32:104‐10.

 

Derogatis LR, Morrow GR, Fetting J, et al. The

prevalence of psychiatric disorders among

cancer patients. JAMA 1983;249:751‐7.

 

De Sloover Koch Y, Ernst ME. Selective

serotonin‐reuptake inhibitors for the

treatment of hot flashes. Ann

Pharmacother 2004;38:1293‐6.

 

Endicott J. Measurement of depression in

patients with cancer. Cancer

1984;53:2243‐9.

 

Fallowfield L, Jenkins V. Current concepts of

communication skills training in oncology.

Recent Results Cancer Res

2006;168:105‐12.

 

Fawzy FI, Fawzy NW, Arndt LA, et al. Critical

review of psychosocial interventions in

 

 

- 100 -

 

cancer care. Arch Gen Psychiatry

1995;52:100‐13.

 

Fisch MJ, Loehrer PJ, Kristeller J, et al.

Fluoxetine versus placebo in advanced

cancer outpatients: A double‐blinded trial

of the Hoosier Oncology Group. J Clin

Oncol 2003;21:1937‐43.

 

Gil F, Grassi L, Travado L, et al. Use of distress

and depression thermometers to measure

psychosocial morbidity among southern

European cancer patients. Support Care

Cancer 2005;13:600‐6.

 

Goodwin PJ, Leszcz M, Ennis M, et al. The

effect of group psychosocial support on

survival in metastatic breast cancer. N

Engl J Med 2001;345:1719‐26.

 

Grassi L, Rosti G. Psychiatric and psychosocial

concomitants of abnormal illness

behaviour in patients with cancer.

Psychother Psychosom 1996;65:246‐52.

 

Grassi L. Uchitomi Y. Depression and

depressive disorders in cancer patients. In:

Johansen C, Grassi L, Costa A eds. Online

multilingual core‐curriculum in

psychosocial aspects of cancer care.

International Psycho‐Oncology Society,

IPOS, 2006 (available at: http://www.ipos-

society.org/ professionals/meetings‐

ed/ed‐online‐lectures.htm, accessed

August 28, 2008).

 

Grassi L, Biancosino B, Marmai L, et al. Effect

of reboxetine on major depressive

disorder in breast cancer patients: An

open‐label study. J Clin Psychiatry

2004;65:515‐20.

 

Grassi L, Holland JC, Johansen C, et al.

Psychiatric concomitants of cancer,

screening procedures, and training of

health care professionals in oncology: The

paradigms of psycho‐oncology in the

psychiatry field. In: Christodoulou GN, Ed.

Advances in Psychiatry, Second Volume.

World Psychiatric Association:

2005a. 59‐66.

 

Grassi L, Malacarne P, Maestri A, et al.

Depression, psychosocial variables and

occurrence of life events among patients

with cancer. J Affect Disord

1997;44:21‐30.

 

Grassi L, Mangelli L, Fava GA, et al.

Psychosomatic characterization of

Adjustment Disorders in the medical

setting. Some suggestions for DSM‐V. J

Affect Disord 2007;101:251‐4.

 

Grassi L, Rosti G, Lasalvia A, et al. Psychosocial

variables associated with mental

adjustment to cancer. Psychooncology

1993;2:11‐20.

 

Grassi L, Sabato S, Rossi E, et al. The use of

the Diagnostic Criteria for Psychosomatic

Research (DCPR) in oncology. Psychother

Psychosoma 2005b;74:100‐7.

 

Greaves MW. Itch in systemic disease:

Therapeutic options. Dermatol Ther

2005;18:323‐7.

 

Hjerl K, Andersen EW, Keiding N, et al.

Depression as a prognostic factor for

breast cancer mortality. Psychosomatics

2003;44:24‐30.

 

Heaven CM, Maguire P. The psychological

impact of cancer on patients' partners and

 

- 101 -

 

other key relatives: A review. Eur J Cancer

2003;39:1517‐24.

 

Hem E, Loge JH, Haldorsen T, et al. Suicide risk

in cancer patients from 1960 to 1999. J

Clin Oncol 2004;22:4209‐16.

 

Hewitt M, Rowland JH. Mental health service

use among adult cancer survivors: Analysis

of the National Health Interview Survey. J

Clin Oncol 2002;20:4581‐90.

 

Holland J.C. History of psycho‐oncology:

overcoming attitudinal and conceptual

barriers. Psychosom Med.

2002;64:206‐221.

 

Holland JC, Andersen B, Breitbart WS, et al.

NCCN. Distress management. J Natl Compr

Canc Netw 2007;5:66‐98.

 

Holland JC, Bultz BD. National comprehensive

Cancer Network (NCCN). The NCCN

guideline for distress management: A case

for making distress the sixth vital sign. J

Natl Compr Canc Netw 2007;5:3‐7.

 

Holland JC, Greenberg DB, Hughes MK. eds.

Quick reference for oncology clinicians:

The psychiatric and psychological

dimensions of cancer symptom

management. Charlottesville: IPOS

Press; 2006.

 

Holland JC, Romano SJ, Heiligenstein JH, et al.

A controlled trial of fluoxetine and

desipramine in depressed women with

advanced cancer. Psychooncology.

1998;7:291‐300.

 

Homsi J, Walsh D, Nelson KA.

Psychostimulants in supportive care.

Support Care Cancer 2000;8:385‐97.

 

Jehn CF, Kuehnhardt D, Bartholomae A, et al.

Biomarkers of depression in cancer

patients. Cancer 2006;107:2723‐9.

 

Jenkins V, Fallowfield L, Solis‐Trapala I, et al.

Discussing randomised clinical trials of

cancer therapy: Evaluation of a Cancer

Research UK training programme. BMJ

2005;330(7488):400.

 

Jin Y, Desta Z, Stearns V, et al. CYP2D6

genotype, antidepressant use, and

tamoxifen metabolism during adjuvant

breast cancer treatment. J Natl Cancer Inst

2005;97:30‐9.

 

Kadan‐Lottick NS, Vanderwerker LC, Block SD,

et al. Psychiatric disorders and mental

health service use in patients with

advanced cancer: A report from the

coping with cancer study. Cancer

2005;104:2872‐81.

 

Kawase E, Karasawa K, Shimotsu S, et al.

Evaluation of a one‐question interview for

depression in a radiation oncology

department in Japan. Gen Hosp Psychiatry

2006;28:321‐2.

 

Kelsen DP, Portenoy RK, Thaler HT, et al. Pain

and depression in patients with newly

diagnosed pancreas cancer. J Clin Oncol

1995;13:748‐55.

 

Kim HF, Fisch MJ. Antidepressant use in

ambulatory cancer patients. Curr Oncol

Rep 2006;8:275‐81.

 

Kissane DW, Clarke DM, Street AF.

Demoralization syndrome. A relevant

psychiatric diagnosis for palliative care. J

Palliat Care 2001;17:12‐21.

 

Kissane DW, Grabsch B, Clarke DM, et al.

Supportive‐expressive group therapy for

women with metastatic breast cancer:

Survival and psychosocial outcome from a

randomized controlled trial.

Psychooncology 2007;16:277‐86.

 

Kissane DW, McKenzie DP, Bloch S. Family

coping and bereavement outcome. Palliat

Med 1997;11:191‐201.

 

Kissane DW, McKenzie M, McKenzie DP, et al.

Psychosocial morbidity associated with

patterns of family functioning in palliative

care: Baseline data from the Family

Focused Grief Therapy controlled trial.

Palliat Med 2003;17:527‐37.

 

Konuk N, Atasoy N, Atik L, et al. Open‐label

study of adjunct modafinil for the

treatment of patients with fatigue,

sleepiness, and major depression treated

with selective serotonin reuptake

inhibitors. Adv Ther 2006;23:646‐54.

 

Lawrie I, Lloyd‐Williams M, Taylor F. How do

palliative medicine physicians assess and

manage depression. Palliat Med

2004;18:234‐8.

 

Lloyd‐Williams M, Taylor F, Dennis M. Is

asking patients in palliative care, "Are you

depressed?" appropriate? Prospective

study. BMJ 2003;327:372‐3.

 

Mangelli L, Fava GA, Grandi S, et al. Assessing

demoralization and depression in the

setting of medical disease. J Clin

Psychiatry 2005;66:391‐4.

 

Massie MJ. Prevalence of depression in

patients with cancer. J Natl Cancer Inst

Monogr 2004;32:57‐71.

 

- 102 -

 

McClain CS, Rosenfeld B, Breitbart W.: Effect

of spiritual well‐being on end‐of‐life

despair in terminally‐ill cancer patients

Lancet. 2003;361:1603‐1607.

 

Mermelstein HT, Lesko L. Depression in

patients with cancer. Psychooncology

1992;1:199‐215.

 

Middelboe T, Ovesen L, Mortensen EL, Bech

P.: Depressive symptoms in cancer

patients undergoing chemotherapy: a

psychometric analysis.Psychother

Psychosom. 1994;61:171‐177.

 

National Comprehensive Cancer Network.

NCCN Clinical Practice Guidelines in

Oncology™. Distress management‐NCCN,

2008 (available at http://www.nccn.org/

professionals/physician gls/f

guidelines.asp, accessed on August 29,

2008).

 

Newell SA, Sanson‐Fisher RW, Savolainen NJ.

Systematic review of psychological

therapies for cancer patients: Overview

and recommendations for future research.

J Natl Cancer Inst 2002;94:558‐84.

 

O'Mahony S, Goulet J, Kornblith A, et al.

Desire for hastened death, cancer pain

and depression: Report of a longitudinal

observational study. J Pain Symptom

Manage 2005;29:446‐57.

 

Onitilo AA, Nietert PJ, Egede LE. Effect of

depression on all‐cause mortality in adults

with cancer and differential effects by

cancer site. Gen Hosp Psychiatry

2006;28:396‐402.

 

Orr K, Taylor D. Psychostimulants in the

treatment of depression: A review of the

evidence. CNS Drugs 2007;21:239‐57.

 

Pae CU, Kim YJ, Won WY, et al. Paroxetine in

the treatment of depressed patients with

haematological malignancy: An open‐label

study. Hum Psychopharmacol.

2004;19:25‐9.

 

Parker PA, Baile WF, de Moor C, et al.

Psychosocial and demographic predictors

of quality of life in a large sample of

cancer patients. Psychooncology

2003;12:183‐93.

 

Pirl WF. Evidence report on the occurrence,

assessment, and treatment of depression

in cancer patients. J Natl Cancer Inst

Monographs 2004;32:32‐9.

 

Raison C, Miller AH. Depression in cancer:

New developments regarding diagnosis

and treatment. Biol Psychiatry

2003;54:283‐94.

 

Reiche EM, Morimoto HK, Nunes SM. Stress

and depression‐induced immune

dysfunction: Implications for the

development and progression of cancer.

Int Rev Psychiatry 2005;17:515‐27.

 

Rodin G, Lloyd N, Katz M, et al. Supportive

care guidelines group of cancer care

Ontario program in evidence‐based care.

The treatment of depression in cancer

patients: A systematic review. Support

Care Cancer 2007;15:123‐36.

 

Rodin G, Voshart K. Depression in the

medically ill: An overview. Am J Psychiatry

1986;143:696‐705.

 

- 103 -

 

Schwartz L, Lander M, Chochinov HM. Current

management of depression in cancer

patients. Oncology 2002;16:1102‐10

 

Sellick SM, Crooks DL. Depression and cancer:

An appraisal of the literature for

prevalence, detection, and practice

guideline development for psychological

interventions. Psychooncology

1999;8:315‐33.

 

Sharpe M, Strong V, Allen K, et al. Major

depression in outpatients attending a

regional cancer centre: Screening and

unmet treatment needs. Br J Cancer

2004;90:314‐20.

 

Sharpe M, Strong V, Allen K, et al.

Management of major depression in

outpatients attending a cancer centre: A

preliminary evaluation of a

multicomponent cancer nurse‐delivered

intervention. Br J Cancer 2004;90:310‐3.

 

Sheard T, Maguire P. The effect of

psychological interventions on anxiety and

depression in cancer patients: Results of

two meta‐analyses. Br J Cancer

1999;80:1770‐80.

 

Soygur H, Palaoglu O, Akarsu ES, et al.

Interleukin‐6 levels and HPA axis

activation in breast cancer patients with

major depressive disorder. Prog

Neuropsychopharmacol Biol Psychiatry

2007;31:1242‐7.

 

Spiegel D, Bloom JR, Kraemer HC, et al. Effect

of psychosocial treatment on survival of

patients with metastatic breast cancer.

Lancet 1989;2:888‐91.

 

Spiegel D, Butler LD, Giese‐Davis J, et al.

Effects of supportive‐expressive group

therapy on survival of patients with

metastatic breast cancer: A randomized

prospective trial. Cancer 2007;110:1130‐8.

 

Spiegel D, Giese‐Davis J. Depression and

cancer: Mechanisms and disease

progression. Biol Psychiatry 2003;

54:269‐82.

 

Spiegel D, Sands S, Koopman C. Pain and

depression in patients with cancer. Cancer

1994;74:2570‐8.

 

Theobald DE, Kirsh KL, Holtsclaw E, et al. An

open label pilot study of citalopram for

depression and boredom in ambulatory

cancer patients. Palliat Support Care

2003;1:71‐7.

 

Torta R, Berra C, Binaschi L, et al. Amisulpride

in the short‐term treatment of depressive

and physical symptoms in cancer patients

during chemotherapies. Support Care

Cancer 2007;15:539‐46.

 

Torta R, Siri I, Caldera P. Sertraline

effectiveness and safety in depressed

oncological patients. Support Care Cancer

2008;16:83‐91.

 

Uchitomi Y, Kugaya A, Akechi T, et al. Three

sets of diagnostic criteria for major

depression and correlations with

serotonin‐induced platelet calcium

mobilization in cancer patients.

Psychopharmacology 2001;153:244‐8.

 

Valentine AD. Cancer pain and depression:

Management of the dual‐diagnosed

patient. Curr Pain Headache Rep 2003

7:262‐9.

 

- 104 -

 

Van der Lee ML, van der Bom JG, Swarte NB,

et al. Euthanasia and depression: A

prospective cohort study among

terminally ill cancer patients. J Clin Oncol

2005;23:6607‐12.

 

von Ammon Cavanaugh S. Depression in the

medically ill. Critical issues in diagnostic

assessment. Psychosomatics

1995;36:48‐59.

 

Walker LG, Heys SD, Walker MB, et al.

Psychological factors can predict the

response to primary chemotherapy in

patients with locally advanced breast

cancer. Eur J Cancer 1999;35:1783‐8.

 

Watson M, Haviland JS, Greer S, et al.

Influence of psychological response on

survival in breast cancer: A population‐

based cohort study. Lancet

1999;354:1331‐6.

 

Watson M, Homewood J, Haviland J, et al.

Influence of psychological response on

breast cancer survival: 10‐year follow‐up

of a population‐based cohort. Eur J Cancer

2005;41:1710‐4.

 

- 105 -

 

Williams S, Dale J. The effectiveness of

treatment for depression/depressive

symptoms in adults with cancer: A

systematic review. Br J Cancer

2006;94:372‐90.

 

Wilson KG, Chochinov HM, McPherson CJ, et

al. Desire for euthanasia or physician‐

assisted suicide in palliative cancer care.

Health Psychol 2007;26:314‐23.

 

World Health Organization.

http://www.who.int/

mediacentre/factsheets/fs297/en/.2006.

 

Yoshikawa E, Matsuoka Y, Yamasue H, et al.

Prefrontal cortex and amygdala volume in

first minor or major depressive episode

after cancer diagnosis. Biol Psychiatry

2006;59:707‐12.

 

Zabora J, BrintzenhofeSzoc K, Curbow B, et al.

The prevalence of psychological distress

by cancer site. Psychooncology

2001;10:19‐28.

 

 

Глава 7